

This report summarizes the overall trends in grant and contract activity across all three campuses of the University of Michigan through the first half of Fiscal Year 2019, which ended December 31, 2018.

Figure 1 shows that total research expenditures through the first half of FY 2019 are ahead of the previous year by 3.1 percent. It is important to note that total research expenditures for FY 2018, which closed on June 30, 2018, reached a record high of \$1.55 billion.

The number of research submissions through December was down 4.5 percent when compared to last year, as shown in Figure 2. Figure 3, however, shows the value of those submissions is up 10.5 percent when compared to FY 2018.


Figures 4 and 5 show the number of new research awards from external sponsors are up 0.3 percent, and their value increased by 1.4 percent when compared to the previous fiscal year—led in December by a four-year, \$3 million award to explore technology-based intervention for reducing sexually transmitted infections and substance use during pregnancy.

S. Jack Hu, Vice President for Research

Craig Reynolds, Executive Director, Office of Research and Sponsored Projects

Figure 1

Expenditures



FY 2017: \$738,578,373
 FY 2018: \$770,026,135
 FY 2019: \$793,912,194

Figure 2

Submissions By Count




Figure 3

Submissions By Amount





Figure 4


Awards By Count



FY 2017: 1,590
 FY 2018: 1,543
 FY 2019: 1,548

Figure 5

Awards By Amount



FY 2017: \$724,985,326
 FY 2018: \$826,964,049
 FY 2019: \$838,163,356

Figure 6

20 Largest Project Awards: December 2018

Principal Investigator	Department	Award Title	Sponsor	Award Sponsor Total	Estimated Award Duration (years)
Tzilos Wernette, Golfo	Family Medicine	Technology-Based Intervention For Reducing Sexually Transmitted Infections and Substance Use During Pregnancy	Health and Human Services, Department of-National Institutes of Health	\$3,091,367	4.8
Courant, Paul	ICPSR-Admin	College and Beyond II: Outcomes of a Liberal Arts Education	Mellon, Andrew W., Foundation	\$3,000,000	2.5
Qi, Ling	Molec & Integrative Physiology	Interplay between SerpinB1 and TLR2/TLR4 in beta cell regeneration	Health and Human Services, Department of-National Institutes of Health	\$2,547,162	5.0
Robinson, Terry	LSA Psychology	Animal Models of Addiction	Health and Human Services, Department of-National Institutes of Health	\$2,425,063	5.0
Hyde, Luke	LSA Psychology	Mechanisms Underlying Resilience to Neighborhood Disadvantage	Health and Human Services, Department of-National Institutes of Health-Subcontracts	\$2,174,231	4.8
Kunkel, Steve	Fast Forward Med Innovation	UM MTRAC Hub for Life Science Innovation (UM-MTRAC Hub)	Michigan, State of, Economic Development Corporation	\$2,000,000	1.0
Carruthers, Vernon	Microbiology and Immunology	Rational design of CNS-permeable cathepsin L inhibitors for treatment of chronic toxoplasmosis	Health and Human Services, Department of-National Institutes of Health	\$1,325,753	3.0
O'Brien, Patrick	Biological Chemistry Dept	Chemistry and Biology of DNA Ligation	Health and Human Services, Department of-National Institutes of Health	\$1,198,287	4.0
Kretzler, Matthias	Int Med-Nephrology	The Renal Pre-Competitive Consortium (RPC2) - Janssen (2019-2021)	Janssen Pharmaceuticals, Inc.	\$1,091,170	3.0
Garikipati, Krishnakumar	Mechanical Engineering	Artificial Intelligence guided multi-scale multi-physics framework for discovering complex emergent materials phenomena	Defense, Department of-Defense Advanced Research Projects Agency (DARPA)	\$1,000,000	1.5
Birdsong, William	Pharmacology Department	Opioid control of midline thalamo-cortico-striatal glutamate transmission.	Health and Human Services, Department of-National Institutes of Health	\$842,400	3.0
Riseng, Catherine	SEAS Michigan Sea Grant	Advancing Stormwater Mangement at Marinas in the Great Lakes	Great Lakes Protection Fund	\$830,000	3.0
Alva, Ajjai	Int Med-Hematology/Oncology	An Open-label, Multicenter, Phase 1b Study of JNJ-63723283, a PD-1 Inhibitor, Administered in Combination with Apalutamide in Subjects with Metastatic ..	Janssen Research and Developme	\$757,260	10.0
Elias, Carol	Molec & Integrative Physiology	Integrative Approaches to Decipher Genetic Determinants of Disease Penetrance in Prokineticin 2 Pathway Related Human Reproductive Disorders	Massachusetts General Hospital	\$735,795	4.7
Palmbo, Phillip	Int Med-Hematology/Oncology	A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy	Immunomedics	\$668,816	10.0
Sorrell, Paula	UMOR Economic Growth Institute	University of Michigan Global Detroit Entrepreneur-in-Residence Program	Global Detroit	\$662,596	3.0
Spitz, Joshua	LSA Physics	Known-Energy Neutrinos for Studying the Nature of Matter	Heising-Simons Foundation	\$643,875	3.0
Koeppel, Robert	Department of Radiology	Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease	Health and Human Services, Department of-National Institutes of Health-Subcontracts	\$628,124	5.0
Kaffenberger, Samuel	Urology	A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined with Intravesical BCG in Participants with BCG-Unresponsive, ..	Bristol-Myers Squibb Company	\$612,352	7.1
Malani, Preeti	Healthcare Policy & Innov-IHPI	University of Michigan National Poll on Healthy Aging	AARP	\$600,000	2.0